Format

Send to

Choose Destination
Nat Rev Cancer. 2004 Dec;4(12):937-47.

Targeting the mitogen-activated protein kinase cascade to treat cancer.

Author information

1
Molecular Sciences and Technologies, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA. Judith.Leopold@pfizer.com

Abstract

The RAS-mitogen activated protein kinase (MAPK) signalling pathway has long been viewed as an attractive pathway for anticancer therapies, based on its central role in regulating the growth and survival of cells from a broad spectrum of human tumours. Small-molecule inhibitors designed to target various steps of this pathway have entered clinical trials. What have we recently learned about their safety and effectiveness? Will the MAPK pathway prove amenable to therapeutic intervention?

PMID:
15573115
DOI:
10.1038/nrc1503
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center